EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh

Margaret L Prust iD, Christina M Lalama iD, Sylvia Kehlenbrink, Olatubosun Akinnola Akinola, Renatus Nyarubamba, Ajmina Hasan Flabe, Abigail Foulds, Graham D Ogle, Edna Majaliwa, Bedowra Zabeen, Kaushik Ramaiya iD, Alana Garvin und 1 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0333652 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Margaret L Prust und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinton Health Access Initiative, Inc. (CHAI), Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Glargine, Insulin, Isophane, Hypoglycemic Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting insulin analogues are the standard of care for Type 1 diabetes (T1D) in high-income countries but remain inaccessible in many low-resource settings. Cost-effectiveness is a key consideration for their adoption. This analysis evaluated the cost-effectiveness of biosimilar insulin glargine (IGlar) versus neutral protamine Hagedorn (NPH) insulin in youth with T1D in Tanzania and Bangladesh.

Methods

Data from the HumAn-1 trial informed a short-term economic model comparing NPH and IGlar over 12 months. The analysis, conducted from a health systems perspective, incorporated micro-costing data for insulin, injection supplies, blood glucose monitoring, and estimated hospitalization costs for complications. Effectiveness was based on a reduction in nocturnal hypoglycemia. In both countries, we calculated incremental cost-effectiveness ratios per quality-adjusted life year (QALY) gained in scenarios that compared IGlar against NPH across delivery devices (i.e., vials, cartridges, single-use pens).

Results

IGlar was cost-effective compared to NPH when provided in cartridges in Bangladesh at a threshold of three times gross domestic product per capita. Other delivery devices in Bangladesh and all options in Tanzania were not cost-effective at current prices. If offered, IGlar vials would be cost-effective in Tanzania and Bangladesh if the price introduced was no more than 32% or 134% higher, respectively, than the current prices of NPH vials. Annual per patient costs and other cost-effectiveness thresholds were explored.

Conclusion

In low-resource settings, IGlar can be a cost-effective alternative to NPH, largely due to reduced nocturnal hypoglycemia, but the delivery device for the insulin has a major impact on the costs and cost-effectiveness comparisons.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin GlargineInsulin, IsophaneHypoglycemic AgentsHumansTanzaniaBangladeshCost-Benefit AnalysisAdolescentMaleFemaleQuality-Adjusted Life YearsChildModels, Economic

Substanzen

Insulin GlargineInsulin, IsophaneHypoglycemic Agents

Autor:innen und Institutionen

  • Clinton Health Access Initiative, Inc. (CHAI), Boston, Massachusetts, United States of America.
  • Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
  • Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Tanzania Diabetes Association, Dar es Salaam, Tanzania.
  • Paediatric Diabetes Care and Research Center, Diabetic Association of Bangladesh, Dhaka, Bangladesh.
  • Life for a Child, Diabetes Australia, Sydney, Australia.

ORCID-Profile: Margaret L Prust, Christina M Lalama, Kaushik Ramaiya

Förderung

  • Leona M. and Harry B. Helmsley Charitable Trust

Zitieren

APA

Prust, M. L., Lalama, C. M., Kehlenbrink, S., Akinola, O. A., Nyarubamba, R., Flabe, A. H., Foulds, A., Ogle, G. D., Majaliwa, E., Zabeen, B., Ramaiya, K., Garvin, A., & Luo, J. (2026). Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh. PLOS One. https://doi.org/10.1371/journal.pone.0333652

Vancouver

Prust ML, Lalama CM, Kehlenbrink S, Akinola OA, Nyarubamba R, Flabe AH, et al. Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh. PLOS One. 2026. doi:10.1371/journal.pone.0333652

BibTeX
@article{Prust2026,
  author = {Prust, Margaret L and Lalama, Christina M and Kehlenbrink, Sylvia and Akinola, Olatubosun Akinnola and Nyarubamba, Renatus and Flabe, Ajmina Hasan and Foulds, Abigail and Ogle, Graham D and Majaliwa, Edna and Zabeen, Bedowra and Ramaiya, Kaushik and Garvin, Alana and Luo, Jing},
  title = {Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0333652}
}
Kostenlos starten →